nabilone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
cannabinoid receptors agonists	1862	51022-71-0

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: nabilone cesamet LY 109514 LY-109514	cannabinol deriv; RN given refers to cpd without isomeric designation; structure Molecular weight: 372.55 Formula: C24H36O3 CLOGP: 6.72 LIPINSKI: 1 HAC: 3 HDO: 1 TPSA: 46.53 ALOGS: -5.88 ROTB: 6 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

nabilone
cesamet
LY 109514
LY-109514

cannabinol deriv; RN given refers to cpd without isomeric designation; structure

Molecular weight: 372.55
Formula: C24H36O3
CLOGP: 6.72
LIPINSKI: 1
HAC: 3
HDO: 1
TPSA: 46.53
ALOGS: -5.88
ROTB: 6

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
3	mg	O

ADMET properties:

Show entries

Search:

Property	Value	Reference
BA (Bioavailability)	20 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Bocci G, Oprea TI, Benet LZ
S (Water solubility)	0.00 mg/mL	Bocci G, Oprea TI, Benet LZ

Showing 1 to 3 of 3 entries

Previous1Next

Approvals:

Date	Agency	Company	Orphan
Dec. 26, 1985	FDA	MEDA PHARMS

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
White blood cell count abnormal	360.33	25.48	85	4568	6157	63478212
Musculoskeletal stiffness	152.27	25.48	118	4535	184500	63299869
Gait disturbance	144.38	25.48	114	4539	183064	63301305
Somatic symptom disorder	131.53	25.48	32	4621	2628	63481741
Sacroiliitis	130.01	25.48	33	4620	3224	63481145
Rheumatoid arthritis	117.81	25.48	117	4536	253702	63230667
Insomnia	104.97	25.48	102	4551	215150	63269219
Drug hypersensitivity	93.30	25.48	114	4539	310573	63173796
Therapeutic product effect incomplete	90.18	25.48	74	4579	124982	63359387
Mood altered	81.02	25.48	33	4620	14710	63469659

Showing 1 to 10 of 28 entries

Previous1 2 3Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Pelvic pain	98.54	42.11	23	1641	2457	34952810
Terminal insomnia	79.36	42.11	15	1649	573	34954694
Injection site warmth	60.60	42.11	15	1649	2047	34953220
Neck pain	49.13	42.11	24	1640	25325	34929942
Ocular hyperaemia	49.12	42.11	19	1645	11433	34943834
Kidney infection	46.34	42.11	15	1649	5379	34949888
Oral herpes	45.93	42.11	15	1649	5532	34949735
Immune-mediated hepatitis	44.96	42.11	12	1652	2203	34953064
Pain	43.68	42.11	51	1613	204624	34750643
Injection site mass	43.31	42.11	15	1649	6611	34948656

Showing 1 to 10 of 10 entries

Previous1Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Somatic symptom disorder	135.17	21.94	32	5431	2505	79736420
Sacroiliitis	127.55	21.94	33	5430	3721	79735204
Therapeutic product effect incomplete	84.38	21.94	73	5390	141572	79597353
Therapeutic response shortened	77.42	21.94	32	5431	15831	79723094
Mood altered	77.07	21.94	33	5430	17814	79721111
Acute psychosis	69.52	21.94	21	5442	4159	79734766
Ankylosing spondylitis	60.84	21.94	25	5438	12180	79726745
Lip and/or oral cavity cancer	59.07	21.94	14	5449	1099	79737826
Terminal insomnia	57.83	21.94	14	5449	1203	79737722
Mean cell haemoglobin concentration abnormal	57.46	21.94	10	5453	162	79738763

Showing 1 to 10 of 32 entries

Previous1 2 3 4Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	A04AD11	ALIMENTARY TRACT AND METABOLISM ANTIEMETICS AND ANTINAUSEANTS ANTIEMETICS AND ANTINAUSEANTS Other antiemetics
FDA CS	M0003267	Cannabinoids
FDA EPC	N0000175782	Cannabinoid
MeSH PA	D014151	Anti-Anxiety Agents
MeSH PA	D000932	Antiemetics
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D002492	Central Nervous System Depressants
MeSH PA	D005765	Gastrointestinal Agents
MeSH PA	D018373	Peripheral Nervous System Agents
MeSH PA	D011619	Psychotropic Drugs

Showing 1 to 10 of 11 entries

Previous1 2Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Show entries

Search:

Disease	Relation	SNOMED_ID	DOID
Chemotherapy-induced nausea and vomiting	indication	236084000
Depressive disorder	contraindication	35489007
Hypertensive disorder	contraindication	38341003	DOID:10763
Conduction disorder of the heart	contraindication	44808001
Low blood pressure	contraindication	45007003
Chronic heart failure	contraindication	48447003
Schizophrenia	contraindication	58214004	DOID:5419
Hepatic failure	contraindication	59927004
Substance abuse	contraindication	66214007
Psychotic disorder	contraindication	69322001

Showing 1 to 10 of 13 entries

Previous1 2Next

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	8.7	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Show entries

Search:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Cannabinoid receptor 1	GPCR	P21554	CNR1_HUMAN	AGONIST	Ki	8.40	CHEMBL	CHEMBL
Cannabinoid receptor 2	GPCR	P34972	CNR2_HUMAN		Ki	8.20	CHEMBL
Cannabinoid receptor 1	GPCR		CNR1_RAT		Ki	8.66	CHEMBL
Cannabinoid receptor 2	GPCR		CNR2_MOUSE		Ki	8.74	CHEMBL

Showing 1 to 4 of 4 entries

Previous1Next

External reference:

Show entries

Search:

ID	Source
001686	NDDF
15778	MMSL
2N4O9L084N	UNII
31447	RXNORM
322124005	SNOMEDCT_US
38357	MMSL
3930	INN_ID
395806009	SNOMEDCT_US
4019352	VUID
4019352	VANDF

Showing 1 to 10 of 22 entries

Previous1 2 3Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Cesamet	HUMAN PRESCRIPTION DRUG LABEL	1	0187-1231	CAPSULE	1 mg	ORAL	NDA	22 sections
Cesamet	HUMAN PRESCRIPTION DRUG LABEL	1	0187-1231	CAPSULE	1 mg	ORAL	NDA	22 sections

Showing 1 to 2 of 2 entries

Previous1Next